MCID: ALK015
MIFTS: 43

Alk-Positive Anaplastic Large Cell Lymphoma

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Positive Anaplastic Large Cell Lymphoma:

Name: Alk-Positive Anaplastic Large Cell Lymphoma 59
Anaplastic Large Cell Lymphoma, Alk Negative 73
Anaplastic Large Cell Lymphoma, Alk-Positive 73
Alk+ Anaplastic Large Cell Lymphoma 59
Alk+ Alcl 59

Characteristics:

Orphanet epidemiological data:

59
alk-positive anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:



External Ids:

Orphanet 59 ORPHA300895
ICD10 via Orphanet 34 C84.6
ICD10 33 C84.6

Summaries for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Positive Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk negative, is related to lung cancer susceptibility 3 and anaplastic large cell lymphoma. An important gene associated with Alk-Positive Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Gemcitabine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and nk cells, and related phenotypes are endocrine/exocrine gland and neoplasm

Related Diseases for Alk-Positive Anaplastic Large Cell Lymphoma

Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 38)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 29.0 ALK MUC1 STAT3
2 anaplastic large cell lymphoma 27.9 ALK JAK3 MCL1 MUC1 NPM1 STAT3
3 alk-negative anaplastic large cell lymphoma 11.2
4 lymphoma 11.1
5 lymphomatoid papulosis 10.3 ALK NPM1
6 lymphatic system cancer 10.3 ALK NPM1
7 hemophagocytic lymphohistiocytosis 10.2
8 leukemia 10.2
9 esophagitis 10.1
10 adenocarcinoma 10.1
11 inflammatory breast carcinoma 10.1
12 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.1
13 gastroduodenitis 10.1
14 myeloid leukemia 10.1
15 leukemia, chronic lymphocytic 2 10.1
16 leukemia, b-cell, chronic 10.1
17 leukemia, chronic lymphocytic 10.1
18 tetraploidy 10.1
19 neurofibromatosis, type i 10.1
20 hypoxia 10.1
21 neurofibromatosis, type iv, of riccardi 10.1
22 intravascular large b-cell lymphoma 10.1
23 b-cell lymphomas 10.1
24 inflammatory myofibroblastic tumor 10.0 ALK NPM1
25 respiratory system cancer 9.8 ALK STAT3
26 intraneural perineurioma 9.8 ALK MUC1
27 eccrine porocarcinoma 9.8 MUC1 STAT3
28 mucinous adenocarcinoma 9.8 ALK MUC1
29 malignant fibroxanthoma 9.7 ALK MUC1
30 hematologic cancer 9.7 ALK MCL1 NPM1
31 pneumothorax 9.6 ALK MUC1
32 myeloma, multiple 9.5 CCND3 MCL1 STAT3
33 leukemia, acute myeloid 9.4 MCL1 NPM1 STAT3
34 primary cutaneous anaplastic large cell lymphoma 9.4 ALK MUC1 NPM1
35 cell type cancer 9.2 ALK MUC1
36 lymphoma, non-hodgkin, familial 9.1 ALK CCND3 MCL1 NPM1
37 cholangiocarcinoma 9.0 MCL1 MUC1 STAT3
38 reticulosarcoma 8.8 ALK CCND3 MUC1 NPM1

Graphical network of the top 20 diseases related to Alk-Positive Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Positive Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Alk-Positive Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.35 ALK CCND3 JAK3 MCL1 STAT3
2 neoplasm MP:0002006 8.92 ALK CCND3 NPM1 STAT3

Drugs & Therapeutics for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs for Alk-Positive Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4,Phase 2 95058-81-4 60750
2
Etoposide Approved Phase 4,Phase 1,Phase 2 33419-42-0 36462
3
Cisplatin Approved Phase 4,Phase 2 15663-27-1 84093 441203 2767
4
Ifosfamide Approved Phase 4 3778-73-2 3690
5
Vincristine Approved, Investigational Phase 4,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
8
Epirubicin Approved Phase 4 56420-45-2 41867
9
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 53-03-2 5865
10
Doxorubicin Approved, Investigational Phase 4,Phase 1,Phase 2 23214-92-8 31703
11
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
12
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
13
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15
Doxil Approved June 1999 Phase 4,Phase 1,Phase 2 31703
16
Pirarubicin Investigational Phase 4 72496-41-4
17 Dexamethasone acetate Phase 4 1177-87-3
18
Isophosphamide mustard Phase 4 0
19 Alkylating Agents Phase 4,Phase 1,Phase 2
20 glucocorticoids Phase 4,Phase 1,Phase 2
21 Topoisomerase Inhibitors Phase 4,Phase 1,Phase 2
22 Hormone Antagonists Phase 4,Phase 1,Phase 2
23 Hormones Phase 4,Phase 1,Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2
25 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2
26 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
27 Etoposide phosphate Phase 4,Phase 1,Phase 2
28 Immunosuppressive Agents Phase 4,Phase 1,Phase 2
29 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
30 Antirheumatic Agents Phase 4,Phase 1,Phase 2
31 BB 1101 Phase 4
32 Antimitotic Agents Phase 4,Phase 1,Phase 2
33 Antineoplastic Agents, Alkylating Phase 4,Phase 1,Phase 2
34 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Phase 2
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 1,Phase 2
36 Dermatologic Agents Phase 4,Phase 1,Phase 2
37 Folic Acid Antagonists Phase 4
38 Nucleic Acid Synthesis Inhibitors Phase 4
39 Vitamin B Complex Phase 4
40 Antimetabolites Phase 4,Phase 2
41 Antimetabolites, Antineoplastic Phase 4,Phase 2
42 Folate Nutraceutical Phase 4
43 Vitamin B9 Nutraceutical Phase 4
44
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
45
Prednisolone Approved, Vet_approved Phase 1, Phase 2,Phase 2 50-24-8 5755
46
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
47
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2,Phase 2 83-43-2 6741
48
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
49
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
50
Cortisone acetate Approved, Investigational Phase 1, Phase 2,Phase 2 1950-04-4, 50-04-4 5745

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
4 Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
5 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
6 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
7 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
8 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Active, not recruiting NCT00069238 Phase 2 EPOCH
9 CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study Active, not recruiting NCT01719835 Phase 2 Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
10 Risk Stratification of Nodal PTCL Active, not recruiting NCT03040206

Search NIH Clinical Center for Alk-Positive Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Positive Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Positive Anaplastic Large Cell Lymphoma:

41
T Cells, Bone, Nk Cells, Bone Marrow, Breast, Testes, Lymph Node

Publications for Alk-Positive Anaplastic Large Cell Lymphoma

Articles related to Alk-Positive Anaplastic Large Cell Lymphoma:

(show top 50) (show all 111)
# Title Authors Year
1
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. ( 29512859 )
2018
2
Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/I^-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. ( 29609590 )
2018
3
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. ( 29642597 )
2018
4
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. ( 29030834 )
2018
5
Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation: A case report. ( 29952979 )
2018
6
Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib. ( 29622884 )
2018
7
Minimal Change Disease as Initial Presentation of ALK-Positive Anaplastic Large-Cell Lymphoma in a Pediatric Patient. ( 29279700 )
2017
8
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma. ( 28665006 )
2017
9
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of ALK-Positive Anaplastic Large Cell Lymphoma. ( 28675026 )
2017
10
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman [Retraction]. ( 29296088 )
2017
11
ALK-positive anaplastic large cell lymphoma undiagnosed in a patient with tuberculosis: a case report and review of the literature. ( 28490385 )
2017
12
Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. ( 28878445 )
2017
13
ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine. ( 27761194 )
2016
14
Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma. ( 27498729 )
2016
15
ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis. ( 27563714 )
2016
16
Fine-needle aspiration cytology yield as a basis for morphological, molecular, and cytogenetic diagnosis in alk-positive anaplastic large cell lymphoma with atypical clinical presentation. ( 27468968 )
2016
17
ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy. ( 26834485 )
2016
18
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. ( 27795556 )
2016
19
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. ( 27793034 )
2016
20
A positive feedback loop involving the Wnt/I^-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. ( 27821172 )
2016
21
Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. ( 26734914 )
2016
22
Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report. ( 27930548 )
2016
23
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman. ( 27445489 )
2016
24
ALK-positive anaplastic large cell lymphoma: an evolving story. ( 25961700 )
2015
25
The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. ( 25797883 )
2015
26
Metachronous classical Hodgkin's lymphoma and ALK-positive anaplastic large cell lymphoma. ( 25938345 )
2015
27
Endobronchial ALK-Positive Anaplastic Large Cell Lymphoma Presenting Massive Hemoptysis. ( 26508931 )
2015
28
ALK-positive anaplastic large cell lymphoma presenting with hemophagocytic lymphohistiocytosis. ( 26114236 )
2015
29
ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement. ( 25738071 )
2015
30
Intra-abdominal ALK-positive anaplastic large cell lymphoma in a patient with neurofibromatosis type 1. ( 26272700 )
2015
31
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 25421750 )
2015
32
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. ( 25921060 )
2015
33
Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 26420623 )
2015
34
MicroRNA and ALK-positive anaplastic large cell lymphoma. ( 25961697 )
2015
35
ALK-positive anaplastic large cell lymphoma with prominent bone involvement. ( 26018037 )
2015
36
Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. ( 26133723 )
2015
37
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. ( 26338968 )
2015
38
ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern. ( 25674293 )
2014
39
Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant. ( 25971833 )
2014
40
Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult. ( 24696735 )
2014
41
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24509625 )
2014
42
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24297868 )
2014
43
Editor in Chief: Response to Eyre etA al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease" ( 24953081 )
2014
44
ALK Positive Anaplastic Large Cell Lymphoma With Pure Leptomeningeal Involvement: Unique Case Report and Review of the Literature. ( 24407988 )
2014
45
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 25855891 )
2014
46
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 24852617 )
2014
47
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. ( 23975180 )
2014
48
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. ( 22820970 )
2013
49
Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma. ( 23022960 )
2013
50
Leukemic phase of ALK-positive anaplastic large cell lymphoma. ( 23610781 )
2013

Variations for Alk-Positive Anaplastic Large Cell Lymphoma

Expression for Alk-Positive Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Positive Anaplastic Large Cell Lymphoma.

Pathways for Alk-Positive Anaplastic Large Cell Lymphoma

Pathways related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 JAK3 MCL1 MUC1 STAT3
2
Show member pathways
12.43 CCND3 JAK3 STAT3
3
Show member pathways
12.38 ALK JAK3 STAT3
4 12.28 ALK CCND3 JAK3 STAT3
5
Show member pathways
11.85 CCND3 JAK3 MCL1 STAT3
6 11.8 CCND3 JAK3 STAT3
7
Show member pathways
11.57 JAK3 MCL1 STAT3
8
Show member pathways
11.49 MCL1 STAT3
9 11.39 CCND3 MCL1
10 11.34 CCND3 STAT3
11
Show member pathways
11.32 CCND3 JAK3
12 11.29 MCL1 NPM1
13
Show member pathways
11.12 JAK3 STAT3
14
Show member pathways
11.06 JAK3 STAT3
15 11.01 JAK3 STAT3
16 10.98 JAK3 MCL1 MUC1 STAT3
17 10.91 CCND3 STAT3

GO Terms for Alk-Positive Anaplastic Large Cell Lymphoma

Cellular components related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.17 ALK CCND3 JAK3 MCL1 MUC1 NPM1

Biological processes related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.62 ALK MCL1 NPM1 STAT3
2 regulation of apoptotic process GO:0042981 9.61 ALK JAK3 MCL1
3 regulation of cell proliferation GO:0042127 9.58 ALK CCND3 JAK3
4 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.48 MUC1 NPM1
5 response to cytokine GO:0034097 9.46 MCL1 STAT3
6 interleukin-7-mediated signaling pathway GO:0038111 9.37 JAK3 STAT3
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.26 JAK3 STAT3
8 interleukin-15-mediated signaling pathway GO:0035723 9.16 JAK3 STAT3
9 interleukin-21-mediated signaling pathway GO:0038114 8.96 JAK3 STAT3
10 cytokine-mediated signaling pathway GO:0019221 8.92 JAK3 MCL1 MUC1 STAT3

Molecular functions related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.13 CCND3 NPM1 STAT3
2 protein phosphatase binding GO:0019903 8.62 JAK3 STAT3

Sources for Alk-Positive Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....